Involvement of MAPKs, NF-κB and p300 co-activator in IL-1β-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells

Shue Fen Luo, Chih Chung Lin, Hsin Chieh Chen, Wei Ning Lin, I. Ta Lee, Chiang Wen Lee, Li Der Hsiao, Chuen Mao Yang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Cytosolic phospholipase A2 (cPLA2) plays a pivotal role in mediating agonist-induced arachidonic acid release for prostaglandin (PG) synthesis during stimulation with interleukin-1β (IL-1β). However, the mechanisms underlying IL-1β-induced cPLA2 expression and PGE2 synthesis by canine tracheal smooth muscle cells (CTSMCs) have not been defined. IL-1β induced cPLA2 protein and mRNA expression, PGE2 production, and phosphorylation of p42/p44 MAPK, p38 MAPK (ATF2), and JNK (c-Jun) in a time- and concentration-dependent manner, determined by Western blotting, RT-PCR, and ELISA, which was attenuated by the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), or transfection with dominant negative mutants of MEK1/2, p38, and JNK, respectively. Furthermore, IL-1β-induced cPLA2 expression and PGE2 synthesis was inhibited by a selective NF-κB inhibitor (helenalin) or transfection with dominant negative mutants of NF-κB inducing kinase (NIK), IκB kinase (IKK)-α, and IKK-β. Consistently, IL-1β stimulated both IκB-α degradation and NF-κB translocation into nucleus in these cells. NF-κB translocation was blocked by helenalin, but not by U0126, SB202190, and SP600125. MAPKs together with NF-κB-activated p300 recruited to cPLA2 promoter thus facilitating the binding of NF-κB to cPLA2 promoter region and expression of cPLA2 mRNA. IL-1β-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. These results suggest that in CTSMCs, IL-1β-induced cPLA2 expression and PGE2 synthesis was independently mediated through activation of MAPKs and NF-κB pathways and was connected to p300 recruitment and activation.

Original languageEnglish
Pages (from-to)396-407
Number of pages12
JournalToxicology and Applied Pharmacology
Volume232
Issue number3
DOIs
Publication statusPublished - Nov 1 2008
Externally publishedYes

Fingerprint

Cytosolic Phospholipases A2
Interleukin-1
Smooth Muscle Myocytes
Muscle
Canidae
Cells
Dinoprostone
p38 Mitogen-Activated Protein Kinases
Transfection
Phosphotransferases
Chemical activation
Messenger RNA
Phosphorylation
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Dactinomycin
Cycloheximide
Cell Nucleus
Genetic Promoter Regions
Arachidonic Acid

Keywords

  • cPLA
  • IL-1β
  • MAPKs
  • NF-κB
  • PGE

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Involvement of MAPKs, NF-κB and p300 co-activator in IL-1β-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells. / Luo, Shue Fen; Lin, Chih Chung; Chen, Hsin Chieh; Lin, Wei Ning; Lee, I. Ta; Lee, Chiang Wen; Hsiao, Li Der; Yang, Chuen Mao.

In: Toxicology and Applied Pharmacology, Vol. 232, No. 3, 01.11.2008, p. 396-407.

Research output: Contribution to journalArticle

Luo, Shue Fen ; Lin, Chih Chung ; Chen, Hsin Chieh ; Lin, Wei Ning ; Lee, I. Ta ; Lee, Chiang Wen ; Hsiao, Li Der ; Yang, Chuen Mao. / Involvement of MAPKs, NF-κB and p300 co-activator in IL-1β-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells. In: Toxicology and Applied Pharmacology. 2008 ; Vol. 232, No. 3. pp. 396-407.
@article{b8a34b6a77d64952ba78aa601c47bf19,
title = "Involvement of MAPKs, NF-κB and p300 co-activator in IL-1β-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells",
abstract = "Cytosolic phospholipase A2 (cPLA2) plays a pivotal role in mediating agonist-induced arachidonic acid release for prostaglandin (PG) synthesis during stimulation with interleukin-1β (IL-1β). However, the mechanisms underlying IL-1β-induced cPLA2 expression and PGE2 synthesis by canine tracheal smooth muscle cells (CTSMCs) have not been defined. IL-1β induced cPLA2 protein and mRNA expression, PGE2 production, and phosphorylation of p42/p44 MAPK, p38 MAPK (ATF2), and JNK (c-Jun) in a time- and concentration-dependent manner, determined by Western blotting, RT-PCR, and ELISA, which was attenuated by the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), or transfection with dominant negative mutants of MEK1/2, p38, and JNK, respectively. Furthermore, IL-1β-induced cPLA2 expression and PGE2 synthesis was inhibited by a selective NF-κB inhibitor (helenalin) or transfection with dominant negative mutants of NF-κB inducing kinase (NIK), IκB kinase (IKK)-α, and IKK-β. Consistently, IL-1β stimulated both IκB-α degradation and NF-κB translocation into nucleus in these cells. NF-κB translocation was blocked by helenalin, but not by U0126, SB202190, and SP600125. MAPKs together with NF-κB-activated p300 recruited to cPLA2 promoter thus facilitating the binding of NF-κB to cPLA2 promoter region and expression of cPLA2 mRNA. IL-1β-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. These results suggest that in CTSMCs, IL-1β-induced cPLA2 expression and PGE2 synthesis was independently mediated through activation of MAPKs and NF-κB pathways and was connected to p300 recruitment and activation.",
keywords = "cPLA, IL-1β, MAPKs, NF-κB, PGE",
author = "Luo, {Shue Fen} and Lin, {Chih Chung} and Chen, {Hsin Chieh} and Lin, {Wei Ning} and Lee, {I. Ta} and Lee, {Chiang Wen} and Hsiao, {Li Der} and Yang, {Chuen Mao}",
year = "2008",
month = "11",
day = "1",
doi = "10.1016/j.taap.2008.07.019",
language = "English",
volume = "232",
pages = "396--407",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Involvement of MAPKs, NF-κB and p300 co-activator in IL-1β-induced cytosolic phospholipase A2 expression in canine tracheal smooth muscle cells

AU - Luo, Shue Fen

AU - Lin, Chih Chung

AU - Chen, Hsin Chieh

AU - Lin, Wei Ning

AU - Lee, I. Ta

AU - Lee, Chiang Wen

AU - Hsiao, Li Der

AU - Yang, Chuen Mao

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Cytosolic phospholipase A2 (cPLA2) plays a pivotal role in mediating agonist-induced arachidonic acid release for prostaglandin (PG) synthesis during stimulation with interleukin-1β (IL-1β). However, the mechanisms underlying IL-1β-induced cPLA2 expression and PGE2 synthesis by canine tracheal smooth muscle cells (CTSMCs) have not been defined. IL-1β induced cPLA2 protein and mRNA expression, PGE2 production, and phosphorylation of p42/p44 MAPK, p38 MAPK (ATF2), and JNK (c-Jun) in a time- and concentration-dependent manner, determined by Western blotting, RT-PCR, and ELISA, which was attenuated by the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), or transfection with dominant negative mutants of MEK1/2, p38, and JNK, respectively. Furthermore, IL-1β-induced cPLA2 expression and PGE2 synthesis was inhibited by a selective NF-κB inhibitor (helenalin) or transfection with dominant negative mutants of NF-κB inducing kinase (NIK), IκB kinase (IKK)-α, and IKK-β. Consistently, IL-1β stimulated both IκB-α degradation and NF-κB translocation into nucleus in these cells. NF-κB translocation was blocked by helenalin, but not by U0126, SB202190, and SP600125. MAPKs together with NF-κB-activated p300 recruited to cPLA2 promoter thus facilitating the binding of NF-κB to cPLA2 promoter region and expression of cPLA2 mRNA. IL-1β-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. These results suggest that in CTSMCs, IL-1β-induced cPLA2 expression and PGE2 synthesis was independently mediated through activation of MAPKs and NF-κB pathways and was connected to p300 recruitment and activation.

AB - Cytosolic phospholipase A2 (cPLA2) plays a pivotal role in mediating agonist-induced arachidonic acid release for prostaglandin (PG) synthesis during stimulation with interleukin-1β (IL-1β). However, the mechanisms underlying IL-1β-induced cPLA2 expression and PGE2 synthesis by canine tracheal smooth muscle cells (CTSMCs) have not been defined. IL-1β induced cPLA2 protein and mRNA expression, PGE2 production, and phosphorylation of p42/p44 MAPK, p38 MAPK (ATF2), and JNK (c-Jun) in a time- and concentration-dependent manner, determined by Western blotting, RT-PCR, and ELISA, which was attenuated by the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK (SP600125), or transfection with dominant negative mutants of MEK1/2, p38, and JNK, respectively. Furthermore, IL-1β-induced cPLA2 expression and PGE2 synthesis was inhibited by a selective NF-κB inhibitor (helenalin) or transfection with dominant negative mutants of NF-κB inducing kinase (NIK), IκB kinase (IKK)-α, and IKK-β. Consistently, IL-1β stimulated both IκB-α degradation and NF-κB translocation into nucleus in these cells. NF-κB translocation was blocked by helenalin, but not by U0126, SB202190, and SP600125. MAPKs together with NF-κB-activated p300 recruited to cPLA2 promoter thus facilitating the binding of NF-κB to cPLA2 promoter region and expression of cPLA2 mRNA. IL-1β-induced cPLA2 expression and PGE2 production was inhibited by actinomycin D and cycloheximide, indicating the involvement of transcriptional and translational events in these responses. These results suggest that in CTSMCs, IL-1β-induced cPLA2 expression and PGE2 synthesis was independently mediated through activation of MAPKs and NF-κB pathways and was connected to p300 recruitment and activation.

KW - cPLA

KW - IL-1β

KW - MAPKs

KW - NF-κB

KW - PGE

UR - http://www.scopus.com/inward/record.url?scp=53449086884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449086884&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2008.07.019

DO - 10.1016/j.taap.2008.07.019

M3 - Article

C2 - 18708082

AN - SCOPUS:53449086884

VL - 232

SP - 396

EP - 407

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 3

ER -